Top

Published in:

Open Access 01-02-2020 | Levothyroxine | Letter to the Editor

Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

Authors: Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A. Ferran, Pierre-Louis Toutain

Published in: Clinical Pharmacokinetics | Issue 2/2020

Excerpt

We welcome the opportunity to respond to Dr. Nicolas’ comments [1] on our article in Clinical Pharmacokinetics [2]. On one point we can agree, however. The public domain headlines, on what he describes as the “Levothyrox^® scandal”, were indeed sensational, but also proportionate. Beyond this, there is little agreement between us and we therefore respond to his “challenge” (his choice of word) to our “argumentation”. First, however, we make the general observation that he does not serve his own case well, when he takes our opinions out of context, to the point, in some instances, of distortion. Readers of Clinical Pharmacokinetics can be the judge of our two articles, Dr. Nicolas’ challenge to them and this response to his challenge. …

Nicolas P. Comment on: “Why were more than 200 subjects required to demonstrate the bioequivalence of a new formulation of levothyroxine with an old one?”. Clin Pharmacokinet. 2019. https://doi.org/10.1007/s40262-019-00849-y.CrossRefPubMed

Concordet D, Gandia P, Montastruc J-L, Bousquet-Mélou A, Lees P, Ferran AA, et al. Why were more than 200 subjects required to demonstrate the bioequivalence of a new formulation of levothyroxine with an old one? Clin Pharmacokinet. 2019. https://doi.org/10.1007/s40262-019-00812-x.CrossRefPubMedPubMedCentral

Concordet D, Gandia P, Montastruc J-L, Bousquet-Mélou A, Lees P, Ferran A, et al. Levothyrox^® new and old formulations: are they switchable for millions of patients? Clin Pharmacokinet. 2019;58:827–33. https://doi.org/10.1007/s40262-019-00747-3.CrossRefPubMedPubMedCentral

Morais JAG, Lobato Mdo R. The new European Medicines Agency guideline on the investigation of bioequivalence. Basic Clin Pharmacol Toxicol. 2010;106(3):221–5.CrossRef

Anonymous. Draft guidance on levothyroxine sodium. Food and Drug Administration; 2018: p. 2. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM428208.pdf. Accessed 4 Oct 2019.

Yu L, Jiang W, Zhang X, Lionberger R, Makhlouf F, Schuirmann D, et al. Novel bioequivalence approach for narrow therapeutic index drugs. Clin Pharmacol Ther. 2015;97(3):286–91.CrossRef

Jayachandran P, Okochi H, Frassetto LA, Park W, Fang L, Zhao L, et al. Evaluating within-subject variability for narrow therapeutic index drugs. Clin Pharmacol Ther. 2019;105(2):411–6.CrossRef

Anonymous. An open-label, single-dose, randomized, two-period, two-sequence crossover, single-center trial to assess bioequivalence of 600 µg Ievothyroxine new formulation versus old formulation administered orally as 3 white tablets of 200 µg in healthy volunteers. 2014. https://ansm.sante.fr/var/ansm_site/storage/original/application/3606e51c6c64f05e25565a3c5bf840b7.pdf. Accessed 26 Nov 2019.

Gottwald-Hostalek U, Uhl W, Wolna P, Kahaly GJ. New levothyroxine formulation meeting 95–105% specification over the whole shelf-life: results from two pharmacokinetic trials. Curr Med Res Opin. 2017;33(2):169–74.CrossRef

10.

Endrenyi L, Schulz M. Individual variation and the acceptance of average bioequivalence. Drug Inf J. 1993;27(1):195–201.CrossRef

11.

Hammami MM, De Padua SJS, Hussein R, Al Gaai E, Khodr NA, Al-Swayeh R, et al. Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs. BMC Pharmacol Toxicol. 2017;18(1):78.CrossRef

12.

Yu L. Quality and bioequivalence standards for narrow therapeutic index drugs. GPhA 2011 Fall Technical Workshop. FDA; 2011. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM292676.pdf. Accessed 26 Nov 2019.

13.

Anonymous. Tirosint-SOL (levothyroxine sodium) oral solution. 2016. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206977Orig1s000TOC.cfm. Accessed 26 Nov 2019.

14.

Yu Y, Teerenstra S, Neef C, Burger D, Maliepaard M. A comparison of the intrasubject variation in drug exposure between generic and brand-name drugs: a retrospective analysis of replicate design trials. Br J Clin Pharmacol. 2016;81(4):667–78.CrossRef

15.

Hauck WW, Hyslop T, Chen ML, Patnaik R, Williams RL. Subject-by-formulation interaction in bioequivalence: conceptual and statistical issues. FDA Population/Individual Bioequivalence Working Group. Food and Drug Administration. Pharm Res. 2000;17(4):375–80.

16.

Munk A. Connections between average and individual bioequivalence. Stat Med. 2000;19(20):2843–54.CrossRef

Title: Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
Authors: Didier Concordet
Peggy Gandia
Jean-Louis Montastruc
Alain Bousquet-Mélou
Peter Lees
Aude A. Ferran
Pierre-Louis Toutain
Publication date: 01-02-2020
Publisher: Springer International Publishing
Keyword: Levothyroxine
Published in: Clinical Pharmacokinetics / Issue 2/2020
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-019-00851-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2020

Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus

Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects

Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review

Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup

A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia